John F. Carpenter 

Professor Emeritus of Pharmaceutical Sciences at the University of Colorado School of Pharmacy 

Talk: Mechanisms of aggregation and stabilization

John F. Carpenter, Ph.D. is Professor Emeritus of Pharmaceutical Sciences at the University of Colorado School of Pharmacy, and a Co-Founder and former Co-Director of the University of Colorado Center for Pharmaceutical Biotechnology. His research interests include mechanisms for protein degradation and stabilization in pharmaceutical formulations, during bioprocessing and in drug delivery systems. Also, he has worked for several years to define rational strategies for stabilizing proteins and vaccines during freeze-drying and storage in the dried solid. He has published more than 300 peer-reviewed papers and is an inventor of more than 30 issued patents. He is an Editor for Reviews and Commentaries for the Journal of Pharmaceutical Sciences. He serves on the Editorial Advisory Boards for Pharmaceutical Research, The AAPS Journal, Journal of Pharmaceutical Sciences, Current Pharmaceutical Biotechnology, Molecular Pharmaceutics and BioPharm International. He has received several teaching awards and The Ebert Prize. He is a Fellow of the American Association for Advancement of Science, the American Association of Pharmaceutical Scientists (AAPS) and the National Academy of Inventors, and has received the AAPS Research Achievement Award in Biotechnology. He also was a co-founder and an organizer for the Colorado Protein Stability Conferences.

Rina Duko 

President & Co-Founder, BioTools, Inc

Talk- TBD

Rina Dukor is the President & CEO of BioTools, a company she co-founded with Professor Laurence Nafie in 2000. Upon receiving Ph.D. in physical chemistry from the University of Illinois, Chicago (UIC) in 1991, she worked for Amoco (AbbVie) where she pioneered and later commercialized technology for structure elucidation of protein biologics through development of instrumentation, sampling techniques and software. At BioTools she led commercialization of two new revolutionary techniques known as VCD and ROA. Under Dr. Dukor’s leadership, BioTools has cemented a world-wide reputation as a leader in structure characterization of biological and chiral drugs and developer of unique advanced technologies. BioTools has won several Awards, including the R&D 100 Award, known as “Oscars of Technology’. Rina has co-authored over 60 peer-reviewed papers; several review chapters and is a holder of four patents. She is a recipient of several prestigious scientific Awards and serves on several non-profit, academic, and commercial Boards including the Board of Visitors for LAS College at UIC and Scripps Florida

Karl Maluf 

Director of Analytical Services 

Talk: How to Identify and Quantify Adeno-Associated Virus Fill States Using Analytical Ultracentrifugation

N. Karl Maluf Ph. D. is the Director of the Biophysical Characteriztion Core at KBI Biopharma which focuses on the characterization of higher order structure and stability of biological macromolecules.  Dr. Maluf is well know as an expert in Analytical Ultracentrifugation analysis, having more than 25 years of experience in the field and numerous publications utilizing the technique.

Tonya Zeczycki, PhD

Associate Professor & Director, BSOM’s Mass Spectrometry Core Facilities

Talk - TBD

Tonya Zeczycki is an Associate Professor in the Department of Biochemistry and Molecular Biology and Director of the Mass Spectrometry Core Facilities at the Brody School of Medicine at East Carolina University. Applying biophysical, enzymology, and mass spectrometry techniques, her lab focuses on understanding why physiological proteins “go rogue” in neurodegenerative diseases. By examining the structural, mechanistic, and biophysical underpinnings of basic neurodegenerative disease biology, her lab hopes to resolve the long-standing question of how pathological proteins in Parkinson’s, Alzheimer’s, and Alzheimer Disease Related Dementias transform from proteins performing important physiological tasks to ones associated with disease pathologies. 

Jesse Coe

Associate Director, Business Development

Talk: 'Characterization and Control Strategy for an ADC

Profile - TBD